List of Excipients in Branded Drug NIFEDIPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	CROSPOVIDONE
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	FERRIC OXIDE RED
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	HYDROXYPROPYL CELLULOSE
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	HYPROMELLOSE
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	LACTOSE
A-S Medication Solutions	NIFEDIPINE	nifedipine	50090-0695	MAGNESIUM STEARATE

Generic Drugs Containing NIFEDIPINE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	nifedipine	0228-2497	AMMONIA
Actavis Pharma Inc	nifedipine	0228-2497	FERRIC OXIDE YELLOW
Actavis Pharma Inc	nifedipine	0228-2497	FERROSOFERRIC OXIDE
Actavis Pharma Inc	nifedipine	0228-2497	GELATIN
Actavis Pharma Inc	nifedipine	0228-2497	GLYCERIN
Actavis Pharma Inc	nifedipine	0228-2497	PEPPERMINT OIL
Actavis Pharma Inc	nifedipine	0228-2497	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in NIFEDIPINE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
15	AMMONIA
21	ANHYDROUS LACTOSE
1	BROWN IRON OXIDE
4	BUTYLATED HYDROXYTOLUENE
55	CELLULOSE ACETATE
75	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Nifedipine

Last updated: February 26, 2026

What is the Role of Excipients in Nifedipine Formulations?

Excipient selection influences drug stability, bioavailability, manufacturing efficiency, and patient compliance. For nifedipine, a calcium channel blocker used primarily for angina and hypertension, excipients address its low water solubility, stability issues, and controlled-release requirements.

Key Excipients in Nifedipine Formulations:

• Lactose and Microcrystalline Cellulose: Fillers and binders in immediate-release tablets.
• Polyvinylpyrrolidone (PVP): Used to improve solubility and stability.
• Hydroxypropyl Methylcellulose (HPMC): Employed in controlled-release formulations.
• Povidone and Magnesium Stearate: Used as disintegrants and lubricants respectively.

Choice of excipient impacts:

• Bioavailability: Solubilizing agents improve absorption.
• Stability: Antioxidants and pH buffers prevent nifedipine degradation.
• Manufacturing: Flow agents facilitate compression and coating processes.
• Patient Acceptance: Taste-masking and formulation size influence compliance.

How Do Excipient Strategies Vary Between Immediate-Release and Controlled-Release Nifedipine?

Immediate-Release Formulations

Designed for rapid onset, these formulations use excipients like lactose or microcrystalline cellulose. Disintegrants such as sodium starch glycolate facilitate quick drug release.

Controlled-Release Formulations

Aim for sustained plasma levels over extended periods. They employ HPMC or ethylcellulose to regulate drug diffusion. Polymer matrix and coating technologies prevent premature release and improve stability.

What Are the Commercial Opportunities Derived from Excipient Innovations?

1. Enhanced Bioavailability through Novel Solubilizers

Developing excipients like lipid-based carriers or complexing agents can address nifedipine’s poor water solubility, enabling lower doses and improved absorption. This strategy can differentiate generic products with superior pharmacokinetic profiles.

2. Stability-Enhancing Excipient Systems

Inclusion of antioxidants, pH buffers, and chelating agents prolong shelf-life and improve storage conditions. Patents covering such combinations can create barriers for competitors.

3. Controlled-Release Technologies

Innovations in polymer matrices or coating processes can extend patent protection and optimize dosing regimens. Market size for controlled-release nifedipine formulations surpasses immediate-release segments in established markets.

4. Combination Formulations

Using excipients to combine nifedipine with other antihypertensive agents offers opportunities for fixed-dose combinations, simplifying therapy and improving compliance.

5. Customized Excipients for Patient-Centric Formulations

Development of excipient systems for pediatric, geriatric, or dysphagic populations expands market reach and fosters brand differentiation.

What Regulatory and Manufacturing Considerations Influence Excipient Strategy?

• Regulatory Status: Excipients must meet pharmacopeial standards (e.g., USP, EP) and demonstrate safety.
• Compatibility: Compatibility with nifedipine prevents interactions that degrade drug potency.
• Scale-up: Excipients must be available at commercial scale and consistent quality.
• Patent Landscape: Innovating with excipients can create product barriers and extend exclusivity.

How Is the Market for Nifedipine and Its Excipient Components Shaping?

Global sales in nifedipine formulations exceed $1.2 billion annually (IQVIA, 2022). The generic segment grows as patent protections for innovator products expire.

Emerging markets drive demand for affordable formulations, emphasizing excipient cost efficiency. Conversely, premium formulations leveraging novel excipients target developed markets seeking improved therapeutic profiles.

What Are Future Trends in Excipient Development for Nifedipine?

• Bioavailability Enhancers: Formulation strategies incorporating nanotechnology and lipid-based excipients.
• Controlled-Release Innovations: Biodegradable polymers and responsive excipients for pulsatile release.
• Patient-Centric Design: Taste-masking systems and excipients suited for flexible dosing.

Key Takeaways

• Excipient choice for nifedipine influences bioavailability, stability, manufacturing, and compliance.
• Controlled-release formulations dominate the market opportunity and rely on specialized polymers.
• Innovation in solubilizers and stability systems can create differentiation and patent protection.
• Fixed-dose combinations expand therapeutic options, leveraging compatible excipients.
• The market opportunities are driven by patent expirations, emerging markets, and regulatory trends favoring patient-centric formulations.

FAQs

1. What excipients are most critical in nifedipine immediate-release tablets?
Disintegrants like sodium starch glycolate, fillers such as lactose, and lubricants including magnesium stearate are essential for manufacturing and bioavailability.

2. How do controlled-release excipients improve nifedipine therapy?
They sustain drug levels, reduce dosing frequency, and minimize side effects by managing drug release through polymer matrices like HPMC.

3. What are the main challenges in developing excipients for nifedipine?
Ensuring chemical stability, biocompatibility, scalability, and regulatory compliance are primary challenges.

4. Which markets present the greatest opportunities for excipient innovation in nifedipine?
Emerging markets seek cost-effective formulations; developed markets prioritize enhanced efficacy and patient compliance.

5. How can excipient innovation extend patent protection for nifedipine formulations?
Novel excipient combinations or delivery platforms can create new patentable formulations, delaying generic competition.

---

References

[1] IQVIA. (2022). Pharmaceutical Market Outlook.
[2] USP. (2021). United States Pharmacopeia-NF.
[3] European Pharmacopoeia. (2022). European Pharmacopoeia 10.0.